Abingdon Health is delighted to announce the appointment of Lyn Rees as non-executive director and board member. Lyn is an experienced executive in global healthcare and holds positions on the board of AIM-listed companies Yourgene Health plc and Concepta plc.
Lyn was previously Group CEO at British Biocell International (now BBI Group) for over 9 years. Lyn began his role at BBI Group following the acquisition of BBI Holdings by Alere in 2008 and in his time, he oversaw the doubling of revenue growth. Lyn completed 7 acquisitions during his tenure at BBI Group and founded BBI Detection and BBI Animal Health. Lyn holds a degree in Business Studies from the University of Wales.
This appointment comes at an exciting time for Abingdon Health who are leading the UK-RTC in the development of a point of care COVID-19 Antibody test for the UK Government in addition to having increased their manufacturing capacity with two new automated manufacturing lines to meet their growth plans.
Dr Chris Hand, Chairman of Abingdon Health commented:
“I’m delighted to welcome Lyn Rees to the board of Abingdon Health Ltd. Lyn’s experience in the IVD market, especially the rapid lateral flow testing market, will be invaluable as we continue to significantly expand our operations. We are delighted that Lyn will be working with us and I look forward to working with him and my colleagues as we continue to build scale at Abingdon”.
Lyn Rees said:
“I’m excited to be joining Abingdon at this time and I am impressed with the progress the company is making across its operations. In addition, as an illustration of my confidence in the company, I have made an investment alongside my appointment as a non-executive director”.
Abingdon Health is a technology-enabled lateral flow diagnostics company providing innovative rapid testing solutions to a multi-industry, global client base. Located across 3 UK sites, Abingdon Health provides specialist assay development and Smartphone reader division alongside Europe’s largest lateral flow test manufacturing capacity. By combining a multi-disciplinary approach with precision automation Abingdon Health assures product consistency and security of supply for the most complex of assays and markets. Abingdon Health takes projects from initial concept through scale-up and into high-volume manufacturing in addition to accommodating clients looking to transfer their rapid test from third-party developers or manufacturers.
Abingdon Health is headquartered in York, United Kingdom. Visit www.abingdonhealth.com.